Chair: Bernd Mayer, Austria

Tord F Vedoy

Norwegian Institute of Drug and Alcohol Research (SIRUS), Norway

The elusive gateway effect: what do we mean when we talk about nicotine as a gateway drug?

Gunnar Sæbø

Norwegian Institute of Drug and Alcohol Research (SIRUS), Norway

The notion of denormalisation in tobacco policy: a critical assessment in light of e-cigarettes and the possible renormalisation of smoking behavior

Jennifer J. Ware, Amy E. Taylor, Philip Haycock, Jack Bowden, Peter J. Rogers, George Davey Smith, Marcus R. Munafò

MRC Integrative Epidemiology Unit,  University of Bristol, UK

Investigating the causal effect of coffee consumption on smoking behaviour

John D. Pritchard

Imperial Tobacco, UK

Scientific basis for rational policies on vaping in public places

Bruce Clark

Philip Morris International R&D, Switzerland

Assessment of the tobacco heating system (THS) 2.2, a candidate modified risk tobacco product: from concept to early clinical data

Christopher Russell  and Tiffany Hamilton-Barclay

Centre for Drug Misuse Research, UK

Perceived harm reduction benefits of even brief, first time use of an e-cigarette by current smokers

Konstantinos Farsalinos

Onassis Cardiac Surgery Center, Greece

Pitfalls in e-cigarette research methodology, presentation and interpretation: lessons from the current literature

Chair: Peter Beckett, UK

Part I - “Finding goldilocks”; what kind of standards regime is “just right” for the vapour industry; keeping things in perspective

Alberto Simeoni

Centre Europeen de Normalisation

European standard setting via CEN TC 437

Katherine Devlin

President, ECITA, UK

The British Standard Institute standard for e-cigarettes - PAS 54115

Joe Gitchell

Pinney Associates, USA

PANEL – Alberto Simeoni, Yushu Zhu, Katherine Devlin, Clive Bates, Joe Gitchell

11.35 – 11.45 BREAK

 Part II - “Lessons from elsewhere”; what can the vapour industry learn from other sectors?

Jack Henningfield

Pinney Associates, USA

OTC medicines in the USA

David Sweanor

Lessons from the history of product regulation

Inger Wahlberg

IWG Consulting, Sweden

Snus and GothiaTek

Part One - Chair: Kevin Molloy, UK

Based on country reports, a review of the current state of advocacy and identification of the key issues for consumers and advocates, in the light of the proposed regulatory regimes and frameworks across the globe

Part Two- Chair: Paddy Costall, UK

Mastrerclass presentations and discussion with a series of experts in campaigning and communications

Chair: Donna Darvill, Australia

A panel discussion providing practical insights and advice to those working in,
managing, or using mainstream health and smoking cessation services

Linda Bauld

University of Stirling, UK

Smoking cessation services and e-cigarettes

Louise Ross

Leicester Stop Smoking Service, UK

Riccardo Polosa

University of Catania, Italy

The Michael Russell Memorial Oration 2015

"Defining the endgame: why we must separate nicotine from tobacco control policy"

Professor Derek Yach, South Africa

Chair: Delon Human, Switzerland

Karl Lund

SIRUS, Norway

The Scandinavian experience: evidence for the impact of snus on smoking

Ann McNeill

National Addictions Centre, England

Recent evidence on e-cigarette use and its contribution to public health in the UK

Marewa Glover

Massey University, Auckland, New Zealand

E-cigarettes and vaping in New Zealand